ライフサイエンスコーパス: fallypride

1 cated by binding potential (BPND) for [(18)F]fallypride.

2 nalysis and by radioligand assay using (18)F-fallypride.

3 hMSC-D2R80A showed specific binding of (18)F-fallypride.

4 thymic rats was performed by PET using (18)F-fallypride.

5 ET scanning with the D(2)/D(3) ligand [(18)F]fallypride.

6 dopamine D-2/D-3 receptor radioligand, (18)F-fallypride.

7 After intravenous (18)F-fallypride (28-37 MBq) administration, normal rats and r

8 (18)F-fallypride and (18)F-fluoromisonidazole were successfull

9 (18)F-fallypride and (18)F-fluoromisonidazole, two well-establ

10 D(2)/D(3) dopamine receptor ligand [(1)(8)F]fallypride and BOLD fMRI while they performed the Stop-s

11 the spleen were visualized in vivo by (18)F-fallypride and confirmed by immunostaining.

12 a dual-scan PET imaging protocol with [(18)F]fallypride and d-amphetamine to measure DA responsivity

13 alities, including (11)C, (15)O-water, (18)F-fallypride, and L-3,4-dihydroxy-6-(18)F-fluorophenylalan

14 s demonstrate the potential utility of (18)F-fallypride as a PET agent for islet cells.

15 tron emission tomography imaging with [(18)F]fallypride at baseline and after administration of oral

16 sitron emission tomography (PET) with [(18)F]fallypride before and after an oral dose of d-amphetamin

17 of islets by streptozotocin decreased (18)F-fallypride binding in pancreas by greater than 50%, para

18 The decrease in (18)F-fallypride binding in the extrastriatal regions points t

19 (18)F-fallypride binding to isolated rat islets and pancreas w

20 (18)F-fallypride bound to isolated islet cells and pancreatic

21 20, 65-79 years); (ii) pharmacokinetic, 18F-fallypride D2/3 receptor imaging and clinical outcome da

22 accounts for time-dependent changes in (18)F-fallypride displacement.

23 le, we synthesized several transport peptide-fallypride fusion molecules as model systems and determi

24 ans, 19 post-treatment scans); and (iii) 18F-fallypride imaging of an antipsychotic free Alzheimer's

25 ing positron emission tomography with [(18)F]fallypride in 43 human subjects with body mass indices (

26 l decrease in the binding potential of (18)F-fallypride in extrastriatal regions: thalamus (-20%), am

27 Uptake of (18)F-fallypride in the pancreas was confirmed by radiochromat

28 odel was used to study localization of (18)F-fallypride in the pancreas, in vitro and ex vivo.

29 -amphetamine-induced displacements of [(18)F]fallypride in the striatal and extrastriatal brain regio

30 orter for in vivo hMPC PET tracking by (18)F-fallypride is a significant step toward potential noninv

31 r and subsequently studied ex vivo for (18)F-fallypride localization in the pancreas.

32 e high-affinity D(2/3) PET radioligand (18)F-fallypride offers the possibility of measuring both stri

33 ponsiveness that can be measured using (18)F-fallypride PET in a single scanning session.

34 ng of task administration for a single (18)F-fallypride PET protocol and the linearized simplified re

35 hy volunteers underwent a single-bolus (18)F-fallypride PET protocol.

36 or impulsivity and underwent a second [(18)F]fallypride PET scan.

37 or impulsivity and underwent a second [(18)F]fallypride PET scan.

38 d into the spleen and visualized using (18)F-fallypride PET.

39 Using [(18)F]fallypride positron emission tomography and blood oxygen

40 Through the combined use of (18)F-fallypride positron emission tomography and magnetic res

41 26 healthy control subjects underwent [(18)F]fallypride positron emission tomography to measure ventr

42 e used magnetic resonance imaging and [(18)F]fallypride positron emission tomography, respectively, t

43 aseline PET scan with the D2/3 ligand [(18)F]fallypride, rats received 6 mg/kg MPH, orally, twice eac

44 aseline PET scan with the D2/3 ligand [(18)F]fallypride, rats were trained to self-administer cocaine

45 on tomography with [(11)C]NNC-112 and [(18)F]fallypride, respectively.

46 When a single (18)F-fallypride scanning protocol is used, task timing is cri

47 itron emission tomography (PET) using [(18)F]fallypride to determine the effects of the 8-week interv

48 Specific binding of (18)F-fallypride to hD2R hMPCs was demonstrated in vitro and i

49 ron emission tomography was used with [(18)F]fallypride to measure BPND in a midbrain region, encompa

50 rmore, our findings support the use of (18)F-fallypride to measure extrastriatal dopamine release.

51 and positron emission tomography with [(18)F]fallypride to measure striatal dopamine D(2)/D(3) recept

52 The ratio of (18)F-fallypride uptake in the pancreas to reference tissue (e

53 [(18)F]fallypride was used to measure D2/D3 baseline receptor a

54 s with amphetamine and the D2/D3 ligand [18F]fallypride, we found that higher levels of trait impulsi